Healthcare marketing professionals work extremely hard developing copy that is creative, engaging and relevant. When it comes time for translation, it is important that the process followed ensures that the messages that took such great effort and time to develop in English, adapt appropriately for the local cultures and languages. There are several options available, and the process recommended depends on the types of assets along with their purposes. Following are brief overviews on the types of processes we at Lionbridge Life Sciences employ to make sure that content is well-adapted and effectively leveraged for global deployment. Continue reading »
It’s hard to go more than a day without hearing news related to the Affordable Care Act (ACA) – commonly referred to as “ObamaCare.” While the national spotlight remains squarely focused on enrollment, coverage policies and technical setbacks on HealthCare.gov, many outside of healthcare circles are less familiar with the influence of new federal mandates on interpretation services. Although the foundation for legal access to various languages was first created in the 1960s, properly providing interpretation services to Limited English Proficient (LEP) patients has been a challenge. Now, the power of the crowd is being leveraged by forward-looking facilities to provide unprecedented, equal and immediate access to even the least commonly spoken of languages. Continue reading »
As I started to write this blog, I was wondering: are we all on the same page with regard to the definition of a “medical device”? Directive 2007/47/EC defines a medical device as “……any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, together with any accessories, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of:
Lionbridge Life Sciences is looking forward to attending the 5th Annual SCOPE Summit, February 4-6 in Miami, Florida. The conference will undoubtedly be a great opportunity for us to hear from industry leaders and discuss with colleagues the topics that impact clinical trial performance. If you’ll be in attendance, please be sure to stop by booth #39 to visit us. Continue reading »
The International Society for Pharmaceutical Engineering (ISPE) recently released the results of its survey collecting feedback from patients on how the clinical trial packaging materials they received during their clinical trial experience impacted them through the trial process. This report and the content covered will likely be met with great interest by those responsible for managing clinical trials, as pharmaceutical companies worldwide continue to struggle with patient compliance/retention. Continue reading »
On the healthcare front, there’s much ground to cover as well in the area of pricing and reimbursement of innovative pharmaceuticals. In Canada, this is controlled at three levels: by the federal Patented Medicine Prices Review Board, by the 17 federal, provincial and territorial public drug plans, and by the Common Drug Review. A pharmaceutical manufacturer must obtain the approval of 19 different bodies for the price of a new drug in Canada. This hurdle presents a big challenge to drug manufacturers and some say impedes Canadians’ access to innovative medicines. Continue reading »
During the Partnerships conference, we’d like to invite you join us on 20.11.2013 at 19.30 to Café Frauenhuber, Vienna’s oldest coffee house to savor delicious coffees and treats and enjoy a relaxed conversation with your peers and colleagues. We’d love to share the research we’ve collected this year from your industry peers about their attitudes regarding global clinical trials, and to determine how Lionbridge Life Sciences can help you with your own future multilingual needs. Please let us know if you’d like to join us at Café Frauenhuber by registering here.
We all appear to believe that effective global communication has evolved from a “nice to do” to a “must accomplish” business goal. This is particularly important in the world of science and medicine, as more organizations expand their global footprints into emerging countries, opening up new opportunities to communicate effectively with clinicians, patients, regulating bodies, and of course their extended global employee base.
As with any effort as massive as growing globally and communicating effectively, there are a host of structured educational choices (not to mention a growing list of consultants and service providers). Books, events, and webinars are all available, with varying price points and levels of intensity, typically concluding with considerations on what paths to success look like. Continue reading »
By all accounts, The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress, 2-6 November 2013 at The Dublin Convention Centre, is shaping up to be a must-attend event. There will be numerous topics explored, all of great interest to health care researchers, health technology assessors, manufacturers, governments, and patients, as healthcare decision-making policies and processes are under continual review. Continue reading »
Please join us on Wednesday October 30, 10:30 AM EDT | 14:30 GMT for an informative webcast as we discuss strategies for optimizing your global patient recruitment communications.
The clinical trial landscape is changing, with emerging markets accounting for a growing portion of global spending on pharmaceuticals, and the United States no longer acting as the hub for site locations. Effective patient recruitment and retention play a critical role in meeting the requirements of an efficient global trial approach. Continue reading »